ALS

2022 - 11 - 16

Post cover
Image courtesy of "Genetic Engineering & Biotechnology News"

Stress Test: ProJenX's Oral Drug Shows Early Promise vs. ALS (Genetic Engineering & Biotechnology News)

Investigators from ProJenX and clinical partners have published encouraging early safety results for the company's ALS candidate prosetin.

Post cover
Image courtesy of "ALS News Today"

Trial of BIIB105 Enrolling ALS Patients With or Without ATXN2... (ALS News Today)

Phase 1/2 trial, recruiting ALS adults with or without ATXN2 mutations, aims to see if BIIB105 affects TDP-42 by targeting ataxin-2 protein.

Explore the last week